Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT00081874

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Conditions: Leukemia, Mantle Cell Lymphoma, Myelofibrosis

Sex: All

Healthy volunteers: No

Phase: PHASE1, PHASE2

Enrollment: 29

Sponsor: M.D. Anderson Cancer Center

Location: M.D. Anderson Cancer Center Houston Texas

Summary

The goal of this clinical research study is to find the highest safe dose of RAD001 that can be given as a treatment for leukemia, mantle cell lymphoma, or myelofibrosis. Another goal is to learn how effective the dose that is found is as a treatment.

Eligibility Criteria

Inclusion Criteria: 1. Patients with advanced, relapsed or refractory: acute leukemias (AML, ALL), MDS, CMML in transformation with greater than or equal to 10% peripheral blood/bone marrow blasts, CML in blastic phase, agnogenic myeloid metaplasia (AMM), CLL, T-cell leukemia, or mantle cell lymphoma. 2. Serum bilirubin \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT00081874). StuddyBuddy aggregates publicly available trial information.